DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer

Information source: Copenhagen University Hospital at Herlev
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: methylprednisoloneacetate (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Copenhagen University Hospital at Herlev

Official(s) and/or principal investigator(s):
Gro M Qvamme, MD, Principal Investigator

Overall contact:
Charlotte Lanng, MD, Phone: +4544884000, Ext: 89265, Email: chalan01@heh.regionh.dk


A randomised double-blinded study, in which the patients either get methylprednisoloneacetate or saline solution in the mastectomy cavity to evaluate the efficacy of methylprednisoloneacetate in preventing seroma in patients operated for primary breast cancer.

Clinical Details

Official title: Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation?

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: number of punctures

Detailed description: After mastectomy, up to 90 % of patients develops seroma in the cavity. The treatment is puncture, which is a small operation, but many patients have to come several times, and there is a risk of infection. In some cases further treatment can be postponed. Preventing seroma to develop would be an improvement in the treatment of breast cancer patients operated with mastectomy. An earlier study found that the seroma production was significant lower in the group who had Prednison injected directly into the cavity. In this study the patient are divided into two groups: patients who have mastectomy and axillary dissection and patients who have mastectomy and Sentinel Node operation. Each group are examined separately. Using Prednison in patients after operation could be a potential risk, but correct injection into the cavity will seldom give systemic side effects.


Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Female.


Inclusion Criteria:

- women with primary breast cancer or Ductal carcinoma in situ, mastectomy plus either

Sentinel Node or Axillary dissection, signed consent form Exclusion Criteria:

- dissection of the axilla in les than 4 month, treatment with steroids, pregnancy, if

the patient don't speak danish, allergy towards steroid, other medical conditions which the investigator find contradict participating

Locations and Contacts

Charlotte Lanng, MD, Phone: +4544884000, Ext: 89265, Email: chalan01@heh.regionh.dk

Chemistry Laboratorium, Copenhagen University Hospital at Gentofte, Hellerup DK 2900, Denmark; Recruiting
Pal B Szecsi, MD

Department of Breast Surgery, Copenhagen University Hospital at Herlev, Herlev 2730, Denmark; Recruiting
Christen K Axelsson, Sub-Investigator
Birgitte Wegeberg, Nurse, Sub-Investigator
Minea Mortensen, Nurse, Sub-Investigator
Mette Okholm, MD, Sub-Investigator

Additional Information

Starting date: August 2010
Last updated: June 23, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017